Neoadjuvant TCH + Pertuzumab Linked to Better pCR vs T-DM1 + Pertuzumab in Early Breast Cancer
Neoadjuvant docetaxel plus carboplatin and trastuzumab followed by pertuzumab (TCH+P) was associated with improved pathologic complete response rate .
ASCO 2016
Intermittent Docetaxel Non-inferior in 1-year Survival for Patients With CRPC
Intermittent docetaxel could be an option for patients with CRPC.
Web Application Improves Survival in Advanced Lung Cancer
A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.
Weekly Paclitaxel, Bevacizumab Should Be Considered for Second- or Third-line Treatment of NSCLC
Weekly paclitaxel plus bevacizumab significantly improved progression-free survival and objective response rate in NSCLC.
Adding Enzalutamide to Abiraterone + Leuprolide Not Effective for Localized High-risk PCa
Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.
Shorter RT Fractionation Schedule Feasible for Localized Prostate Cancer
A hypofractionated radiotherapy regimen administered in 20 fractions over 4 weeks was noninferior in patients with localized prostate cancer.
Adjuvant Docetaxel Fails to Improve Biochemical DFS in High-risk Prostate Cancer
In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.
TRUS-biopsy Poorly Detects Prostate Cancer
Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.
Double Autologous HCT Improves Outcomes in High-risk Pediatric Neuroblastoma
Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
Extending Hormone Therapy to 10 Years May Reduce Breast Cancer Recurrence Without Negatively Affecting QoL
Extending aromatase inhibitor therapy for 5 years beyond an initial 5 years resulted in a 34% reduction in recurrence in early-stage breast cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2016
Loading... 
Loading...